Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Non-Current Assets: 2009-2025

Historic Non-Current Assets for UNITED THERAPEUTICS (UTHR) over the last 16 years, with Sep 2025 value amounting to $3.9 billion.

  • UNITED THERAPEUTICS's Non-Current Assets rose 23.52% to $3.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 billion, marking a year-over-year increase of 23.52%. This contributed to the annual value of $3.5 billion for FY2024, which is 3.48% down from last year.
  • Per UNITED THERAPEUTICS's latest filing, its Non-Current Assets stood at $3.9 billion for Q3 2025, which was down 5.49% from $4.1 billion recorded in Q2 2025.
  • In the past 5 years, UNITED THERAPEUTICS's Non-Current Assets registered a high of $4.1 billion during Q2 2025, and its lowest value of $2.5 billion during Q2 2021.
  • Its 3-year average for Non-Current Assets is $3.5 billion, with a median of $3.5 billion in 2024.
  • In the last 5 years, UNITED THERAPEUTICS's Non-Current Assets spiked by 35.73% in 2023 and then declined by 12.40% in 2024.
  • UNITED THERAPEUTICS's Non-Current Assets (Quarterly) stood at $2.8 billion in 2021, then fell by 6.37% to $2.7 billion in 2022, then surged by 35.73% to $3.6 billion in 2023, then fell by 3.48% to $3.5 billion in 2024, then increased by 23.52% to $3.9 billion in 2025.
  • Its last three reported values are $3.9 billion in Q3 2025, $4.1 billion for Q2 2025, and $3.8 billion during Q1 2025.